Feb 2, 2023 4:05pm EST Rigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
Jan 18, 2023 8:05am EST National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia